2025/05/14 by Ravi B. Patel, Stephen Adler, Freddy E. Escorcia · 1 voice
Medicine · #Lung Cancer Treatments and Mutations #Medical Imaging and Pathology Studies #Radiopharmaceutical Chemistry and Applications
paper · doi:10.1158/1078-0432.ccr-25-0654
openalex publication_date 2025/05/14 · openalex created_date 2025/05/15 · openalex updated_date 2026/08/01
Radiopharmaceuticals, which emit either α or β particles, have changed the landscape of prostate cancer imaging and treatment. Each particle type has unique physical properties that can be exploited to optimize treatment effect. Using murine models of disseminated prostate cancer and a CD46-targeted α particle-emitting radioimmunoconjugate, a recent study shows superior efficacy in mice bearing micrometastastic versus macrometastatic disease. See related article by Bidkar et al., p. 2963.